Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Issue 20 (20th July 2015)

• Record Type: Journal Article
• Authors: Qian, Guoqing; Jiang, Ning; Wang, Dongsheng; Newman, Scott; Kim, Sungjin; Chen, Zhengjia; Garcia, Gabriela; MacBeath, Gavin; Shin, Dong M.; Khuri, Fadlo R.; Chen, Zhuo G.; Saba, Nabil F.
• Is Part Of: Cancer. Volume 121:Issue 20(2015)
• Page Start: 3600
• Page End: 3611
• Publication Date: 2015-07-20
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29549
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29549-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Although heregulin and human epidermal growth factor receptor 3 (HER3) are frequently expressed at high levels in patients with head and neck cancer, their prognostic value remains unclear. The authors explored the prognostic significance of heregulin/HER3 expression in patients with oropharyngeal squamous cell carcinoma (OPSCC), taking into account other HER family members as well as p16 status.</p> </sec> <sec id="cncr29549-sec-0002" sec-type="section"> <title>METHODS</title> <p>Ninety‐six primary tumor specimens from patients with OPSCC were retrospectively collected and analyzed for heregulin messenger RNA (mRNA) using in situ hybridization and for HER3, epidermal growth factor receptor, and human epidermal growth factor receptor 2 (HER2) using quantitative immunohistochemistry. Heregulin and HER3 mRNA levels were also examined among different tumor types using The Cancer Genome Atlas database.</p> </sec> <sec id="cncr29549-sec-0003" sec-type="section"> <title>RESULTS</title> <p>High heregulin mRNA (> the median) correlated significantly with poor overall survival (OS) (hazard ratio [HR], 8.48; 95% confidence interval [95% CI], 2.17‐33.17 [<italic>P</italic> =.002]) but not disease‐free survival (HR, 1.52; 95% CI, 0.64‐3.65 [<italic>P</italic> =.341]) in patients with OPSCC. Heregulin mRNA correlated negatively with OS in both patients with p16‐positive (<italic>P</italic> =.049) and p16‐negative (<italic>P</italic> =.091) OPSCC on univariate analysis. High HER3 (> the median) also correlated with poor OS (HR, 4.68; 95% CI, 1.47‐14.90 [<italic>P</italic> =.009]) on multivariate analysis. Epidermal growth factor receptor levels independently correlated with disease‐free survival (<italic>P</italic> =.025) and inversely correlated with p16 status (<italic>P</italic> =.012). In addition, The Cancer Genome Atlas data demonstrated that head and neck squamous cell carcinoma exhibits higher heregulin expression compared with other solid tumor types examined.</p> </sec> <sec id="cncr29549-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>High heregulin mRNA and high HER3 protein levels were found to independently correlate with poor OS in patients with OPSCC. These data support targeting HER3 in patients with heregulin‐high OPSCC and warrant further clinical investigation. <bold><italic>Cancer</italic> 2015;121:3600–3611</bold>. © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>